Results 211 to 220 of about 253,192 (255)

Neutrophil Extracellular Trap Formation-Derived Peptidylarginine Deiminases in the Citrullination of Oral Bacteria to Promote Inflammation in Rheumatoid Arthritis. [PDF]

J Rheumatol
Acharya S, Brewer RC, Gomez AM, Younis S, Pandit M, Jahanbani S, Sharpe O, Love ZZ, Howard MC, Orange DE, Robinson WH.   +10 more
europepmc   +1 more source

Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor [PDF]

British Journal of Haematology, 1998
Interleukin‐6 (IL‐6) is the major growth factor for human myeloma cells, exerting its effect through the IL‐6 receptor (IL‐6R). A soluble form of IL‐6R (sIL‐6R) has been identified, which increases the sensitivity of myeloma cells to IL‐6. In patients with multiple myeloma (MM), serum concentrations of sIL‐6R are elevated and associated with poor ...
Peter I Croucher, Gillian Murphy, R G Russell   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses

European Journal of Biochemistry, 2001
Signal transduction in response to interleukin‐6 (IL‐6) requires binding of the cytokine to its receptor (IL‐6R) and subsequent homodimerization of the signal transducer gp130. The complex of IL‐6 and soluble IL‐6R (sIL‐6R) triggers dimerization of gp130 and induces responses on cells that do not express membrane bound IL‐6R.
T, Jostock, J, Müllberg, S, Ozbek, R, Atreya, G, Blinn, N, Voltz, M, Fischer, M F, Neurath, S, Rose-John   +8 more
openaire   +2 more sources

Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line

Breast Cancer, 2018
Interleukin-6 (IL-6) is a potent inflammatory cytokine that appears to play a key role in cancer growth and metastasis. In the present study, the effects of IL-6 receptor (IL-6R) on breast cancer aggressiveness and bone metastases were investigated.MDA-MB-231 (MDA-231) cells were treated in the presence or absence of anti-human IL-6 receptor (IL-6R ...
Hiroki, Wakabayashi, Takahiko, Hamaguchi, Nobuto, Nagao, Sho, Kato, Takahiro, Iino, Tomoki, Nakamura, Akihiro, Sudo   +6 more
openaire   +2 more sources

In vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment

Arthritis & Rheumatism, 2011
AbstractObjectiveInterleukin‐6 (IL‐6) receptor inhibition by tocilizumab was recently licensed for the treatment of rheumatoid arthritis (RA). IL‐6 induces in vitro differentiation of B cells into antibody‐forming cells; however, the in vivo effects of IL‐6 inhibition on the B cell compartment are currently not known.
Petra, Roll, Khalid, Muhammad, Mathias, Schumann, Stefan, Kleinert, Hermann, Einsele, Thomas, Dörner, Hans-Peter, Tony   +6 more
openaire   +2 more sources

Tocilizumab: The first interleukin-6-receptor inhibitor

American Journal of Health-System Pharmacy, 2008
The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed.Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R).
openaire   +2 more sources

Significance of Interleukin-6 Signaling in the Resistance of Pharyngeal Cancer to Irradiation and the Epidermal Growth Factor Receptor Inhibitor

International Journal of Radiation Oncology*Biology*Physics, 2010
Tumor eradication by chemoradiotherapy for pharyngeal cancer has not been particularly successful. Targeting epithelial growth factor receptor (EGFR) could be a potential treatment strategy providing additional benefits, but only a subset of these tumors gives a clinically significant response to EGFR inhibitors.
Chih-Cheng, Chen, Wen-Cheng, Chen, Chang-Hsien, Lu, Wen-Hung, Wang, Paul-Yang, Lin, Kuan-Der, Lee, Miao-Fen, Chen   +6 more
openaire   +2 more sources

Interleukin-6 Receptor Inhibitor Therapy Is Associated with Improved Outcomes in Patients with Severe COVID-19 Disease

SSRN Electronic Journal, 2020
Background: The impact of interleukin-6 receptor inhibitors (IL6ri) on Coronavirus disease 2019 (Covid-19) outcomes remains uncertain. Methods: Patients with severe and critical Covid-19 were given an IL6ri (sarilumab or tocilizumab) based on pragmatic and iteratively reviewed guidelines at a safety net hospital with a diverse population.
Pranay Sinha, Anahita Mostaghim, Catherine G. Bielick, Angela McLaughlin, Davidson H. Hamer, Lee M. Wetzler, Nahid Bhadelia, Maura A. Fagan, Benjamin P. Linas, Sabrina A Assoumou, Michael H. Ieong, Nina H Lin, Ellen R. Cooper, Karrine D. Brade, Laura F. White, Tamar F. Barlam, Manish Sagar   +16 more
openaire   +1 more source